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ANALISIS FARMAKOEKONOMI KE ATAS KES-KES HIPERTENSI YANG 
TAK RUMIT DI KLINIK RAWATAN AMBULATORI 
ABSTRAK 
Peningkatan ketidaknormalan tekanan darah dikaitkan dengan penyakit-penyakit 
kardiovaskular dan ginjal. Hipertensi merupakan masalah utama kesihatan yang 
dihadapi di serata dunia, berdasarkan frekuensinya yang tinggi. Di Malaysia, prevalens 
hipertensi di kalangan umur penduduk ≥ 15 tahun adalah 27.8%. Kos langsung dan kos 
tidak langsung yang tinggi telah dikaitkan dengan hipertensi. Farmakoekonomi 
mengaplikasikan etika dan metodologi ekonomi kesihatan dalam bidang farmaseutikal 
dan polisi farmaseutikal. Kajian ini dijalankan untuk: 1) menganggarkan kos bagi 
merawat hipertensi tanpa komplikasi; 2) menganggarkan impak tekanan darah yang 
tidak terkawal terhadap sumber penjagaan ambulatori; dan 3) menilai keberkesanan kos 
bagi jenis ubat antihipertensi yang berbeza.   
Data telah dicatat secara prospektif pada sekumpulan pesakit hipertensi selama satu 
tahun dan data dianalisis secara retrospektif telah dibuat untuk menentukan kos 
(langsung dan tidak langsung) yang berkaitan dengan pengendalian pesakit hipertensi 
yang tak rumit. Nisbah kos keberkesanan kelas-kelas ubat hipertensi yang berbeza telah 
dikira dan dibuat perbandingan. Ujian tak parametrik (Kruskal Wallis dan Mann-
Whitney) telah digunakan untuk menentukan perbezaan signifikan antara kos dan nilai 
p < 0.05 dianggap sebagai perbezaan yang signifikan.   
Kos-kos langsung berkaitan pengendalian hipertensi pelbagai fasa adalah signifikan  
(prehipertensi (MYR 12.19), fasa 1 (MYR 11. 86)  dan fasa 2  (MYR 14.05)). 
xiv 
 
Kehilangan produktiviti  akibat hipertensi antara ketiga-tiga fasa di atas adalah tidak 
signifikan (prehipertensi (MYR 10.48), fasa 1 (MYR 8.91) dan fasa 2 (9.43)). Kos-kos  
langsung berkaitan dengan hipertensi tak terkawal adalah lebih tinggi  daripada kos-kos 
langsung berkaitan dengan kumpulan hipertensi terkawal pada ketiga-tiga kumpulan 
fasa hipertensi dalam kajian (prehipertensi (MYR 16.79  berbanding MYR 12.19); fasa 
1 (MYR 22.31 berbanding MYR 11.86) dan pada fasa 2 (MYR 17.96 berbanding MYR 
14.05)). Kos tak langsung bulanan berkaitan hipertensi tak terkawal adalah lebih tinggi 
berbanding dengan kos-kos tak langsung yang berkaitan dengan kumpulan hipertensi 
terkawal pada fasa 1 dan fasa 2 dan sebaliknya berlaku fasa prehipertensi (MYR 9.71 
berbanding MYR 10.48), pada fasa 1 (MYR 11.18 berbanding MYR 8.91) dan pada 
fasa 2 (MYR 11.02 berbanding MYR 9.79)). Nisbah kos keberkesanan adalah lebih 
baik untuk kumpulan-kumpulan diuretik (MYR 2364.86), perencat ACE (MYR 
2456.63) dan penghalang beta (MYR 2615.08) daripada penghalang alpha (MYR 
2689.26), daripada kumpulan-kumpulan diuretik berserta penghalang beta (MYR 
3209.34), penghalang saluran kalsium (MYR 3369.60)  dan campuran-campuran lain 
(MYR 6546.06).   
Rumusannya adalah pengurangan kos langsung boleh dicapai dengan kawalan 
hipertensi. Sumber kos rawatan ambulatori adalah lebih tinggi  jika hipertensi tidak 
terkawal. Ini dapat dilihat pada hipertensi tak rumit tidak kira di fasa apa pun dan ia 
boleh meningkatkan kos penyelenggaraan kesihatan Negara Malaysia keseluruhannya. 
Oleh itu, strategi rawatan adalah untuk mengawal hipertensi, tidak kira pada fasa atau 
peringkat apa pun. Kajian ini juga menunjukkan bahawa rawatan dengan diuretik adalah 
xv 
 
paling berkesan kos dalam rawatan hipertensi tak rumit. Akhir kata, analisis 
farmakoekonomi adalah satu cara yang utama yang dapat membantu polisi 
penyelenggaraan kesihatan oleh yang berwajib dengan data yang diperolehi. 
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PHARMACOECONOMIC ANALYSIS OF UNCOMPLICATED 
HYPERTENSION IN AMBULATORY CARE CLINIC 
ABSTRACT 
Abnormal elevation in BP is associated with cardiovascular and renal diseases. 
Prevalence of hypertension in subjects aged ≥ 15 years is 27.8% in Malaysia. Studies 
have reported high direct and indirect costs are attributable to hypertension. 
Pharmacoeconomics implements and applies methodologies of health economics to the 
field of pharmaceuticals and pharmaceutical policy. Malaysia lacks data on how much it 
cost to treat hypertension and what is the size of the economic burden of hypertension. 
This study was done to: 1) estimate the cost of treating uncomplicated hypertension, 2) 
estimate the impact of uncontrolled BP on ambulatory care resources, and 3) evaluate 
the cost-effectiveness of different antihypertensive drug classes.  
Prospective data collection of a cohort of hypertensive patients who had signed the 
informed consent sheet and followed up for one year were analyzed retrospectively to 
determine the costs (direct and indirect) attributable to uncomplicated hypertension. 
Cost-effectiveness ratios of different antihypertensive drug classes were calculated and 
compared. Nonparametric tests (i.e., Kruskal Wallis and Mann-Whitney) were used to 
determine the statistically significant differences in costs and a p value of < 0.05 was 
defined as statistically significant.  
Direct costs attributable to hypertension stages were significantly different 
(prehypertension (MYR 12.19), Stage 1 (MYR 11.86) and Stage 2 (MYR 14.05)). 
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Productivity lost due to hypertension between the three stages were not significantly 
different (prehypertension (MYR 10.48), Stage 1 (MYR 8.91) and Stage 2 (MYR 
9.43)). Direct costs associated with uncontrolled hypertension groups were significantly 
higher than direct costs associated with controlled hypertension groups in all stages of 
hypertension (in prehypertension (MYR 16.79 vs. MYR 12.19), in Stage 1 (MYR 22.31 
vs. MYR 11.86) and in Stage 2 (MYR 17.96 vs. MYR 14.05), respectively. Monthly 
indirect costs associated with uncontrolled hypertension groups were higher than 
indirect costs associated with the controlled hypertension groups in stage 1 and stage 2 
and the opposite was noticed in prehypertension stage (in prehypertension (MYR 9.71 
vs. MYR 10.48), in Stage 1 (MYR 11.18 vs. MYR 8.91) and in Stage 2 (MYR 11.02 vs. 
MYR  9.79). Cost-effectiveness ratio was better for diuretics (MYR 2364.86), ACE 
inhibitors (MYR 2456.63), and beta-blockers (MYR 2615.08) than for alpha-blockers 
(MYR 2689.26), the diuretics and beta-blockers combination therapy (MYR 3209.34), 
calcium channel blockers (MYR 3369.60), and other combinations (MYR 6546.06), 
respectively. 
In conclusion, avoidance of extra direct costs can be accomplished by controlling 
hypertension. Higher ambulatory care resources costs are associated with poorly 
controlled hypertensive individuals. Moreover, uncomplicated hypertension, regardless 
of its stage or severity, may increase the total Malaysian national health costs, and thus, 
treatment strategies for uncomplicated hypertension should target all hypertensive 
patients irrespective of their stage. Additionally, this study indicates that diuretics are 
the most cost effective drug class in managing uncomplicated hypertensive patients. 
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Finally, pharmacoeconomic analysis is an important method of informing health care 









Abnormal elevation in blood pressure is associated with cardiovascular and renal 
diseases. Clinicians believe that identifying and treating large number of patients with 
hypertension is on the top of their list of priorities. Most of the patients diagnosed with 
hypertension have no particular cause. The deleterious effects of high blood pressure 
are seen with the normal range of blood pressure and continue with rising blood 
pressure. There is no sharp distinction between normal and pathologic blood pressure 
level. However, an agreement as to what levels blood pressure is tolerable and what 
levels represent hypertension has been described in clinical practice guidelines. 
Hypertension treatment is still the main goal to reduce cardiovascular and kidney 
diseases as well as stroke morbidity and mortality (Brent, 2004). 
Hypertension is a common disease and is defined as steadily elevated blood pressure. 
Blood pressure increases with age and hypertension is very common in the elderly. In 
most cases, there is unknown path physiology for hypertension particularly in the case 
of essential or primary hypertension. There is no cure for essential or primary 
hypertension. However, the blood pressure can be controlled. The majority (90 %) of 
2 
 
hypertensive patients has essential hypertension; less than 10% have secondary 
hypertension (Dipiro, 2008). Secondary hypertension results from a co-morbid disease 
or drug (Table 1.1). The most common cause of secondary hypertension is severe 
chronic kidney disease (Dipiro, 2008). Drugs can directly or indirectly cause 
hypertension or increase blood pressure (Dipiro, 2008). 
Table 1.1 Secondary Causes of Hypertension 
Disease Drugs associated with hypertension 
Chronic kidney disease  
Coarctation of the aorta  
Obstructive sleep apnea  
Parathyroid disease  
Pheochromocytoma  
Primary aldosteronism  




Corticosteroids,  ACTH 
Estrogens" (usually oral contraceptives with high        
estrogenic activity)  
Nonsteroidal anti-inflammatory drugs, COX-2 inhibitors  
Phenylpropanolamine and analogues  
Cyclosporine and tacrolimus 
Erythropoetin  
Sibutramine 
Antidepressants (especially venlafaxine), bromocriptine, 
buspirone, carbamazepine, clozapine, 
desfulrane, ketamine, metoclopramide  
Clonidine/ β-blocker combination 
Pheochromocytoma: β-blocker without α-blocker first 
 
Street Drugs and Other Natural Products 
Cocaine and cocaine withdrawal 
Ma huang, “herbal ecstasy,” other 
phenylpropanolamine analogues  
Nicotine and nicotine withdrawal, anabolic steroids, 
narcotic withdrawal, methylphenidate, 
phencyclidine, ketamine, ergotamine and other 




Sodium, Ethanol, Licorice, Tyramine-containing foods if 
taking a monoamine oxidase inhibitor 
 
Chemical Elements and Other Industrial Chemicals  
Lead, mercury, thallium and other heavy metals, lithium 
Source: Dipiro, J.T., 2008. 
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Hypertension is a major risk factor for cardiovascular diseases. Coronary heart disease 
is the most common and lethal complication of hypertension and this due to the low 
efficacy of antihypertensive drugs against coronary heart disease (Giuseppe, 2002). 
 
1.1.2 Definition and Classification of Hypertension 
Arterial hypertension is defined as systolic arterial pressure ≥ 140 mmHg and diastolic 
arterial pressure ≥ 90 mmHg. The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 
classified blood pressure in adults (age ≥ 18 years) based on the average of two or 
more accurately measured blood pressure readings from two or more clinical 
encounters (Chobanian et al., 2003). Normal blood pressure values considered a 
systolic blood pressure (SBP) of less than 120 mmHg and a diastolic blood pressure 
(DBP) of less than 80 mmHg, prehypertension stage (SBP of 120-139 or DBP of 
80-89) Stage 1 (SBP of 140-159 or DBP of 90-99) and Stage 2 (SBP ≥ 160 or 
DBP ≥ 100) (Chobanian et al., 2003). The following table provides a classification of 
blood pressure for adults at 18 years of age and older. 
Table 1.2 Classification of Blood Pressure  
Classification Systolic Blood Pressure  
(mmHg) 
 Diastolic Blood Pressure 
(mmHg) 
Normal Less than 120 and Less than 80 
Prehypertension 120-139 or 80-89 
Stage 1  140-159 or 90-99 
Stage 2  Greater than or equal to 160 or Greater than or equal to 
100 
Source: Chobanian et al., (2003b) 
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Hypertensive crises are clinical circumstances where blood pressure values are 
greater than 180/120 mmHg. They are labeled as a hypertensive emergency. This 
category of hypertension is characterized by a great elevation in blood pressure 
that comes with acute or progressing target-organ damage, like encephalopathy, 
intracranial hemorrhage, acute left ventricular failure with pulmonary edema, 
dissecting aortic aneurysm, unstable angina, and eclampsia or severe 
hypertension during pregnancy (Chobanian et al., 2003).  
 
1.1.3 Hypertension Epidemiology   
Systolic blood pressure increases as age increases. Diastolic blood pressure 
increases just until 50 years of age; after that, it becomes steady or decreases to 
some extent. Increasing age will lead to a swing from diastolic pressure to systolic 
pressure and finally to pulse pressures as the chief predictor of cardiovascular 
disease risk (Franklin et al., 2001). At the age of below 50 years, diastolic 
pressure is the strongest predictor for cardiovascular diseases risk. The transition 
period when all three blood pressure signs are similar predictors, starts at the age of 
50-59. From the age of 60 onwards, diastolic pressure is negatively related to the 
risk of cardiovascular diseases, and pulse pressure becomes a superior predictor to 
systolic pressure (Franklin et al., 2001). 
Staessen, et al. (2000) found that in middle-aged and older individuals with 
hypertension, cardiovascular diseases risk worsened with raised pulse pressure; it is 
5 
 
consistent in men and women. Furthermore, the risk increases in treated and 
untreated hypertensive individuals, and in hypertensive patients with a history of 
myocardial infarction (Mitchel et al., 1997) or renal failure (Safar et al., 2002). In 
addition, in older systolic hypertensive patients, ambulatory pulse pressure is a 
stronger predictor of cardiovascular diseases risk than the pulse pressure 
measured by conventional sphygmomanometer, while mean pressure regardless of 
the type of blood pressure measurement, is not predictive (Staessen et al., 2002a). 
Hypertension is the most commonly cited reason for a physician’s office visit. In a 
study based in the United States of America in 2000, over 10 million office visits were 
attributable to high blood pressure (Cherry and Woodwell, 2000). Furthermore, poor 
control or uncontrolled high blood pressure can increase the severity of hypertension, 
and thus, healthcare expenditure, through the number of physician visits or even the 
time interval between the visits to seek health care (Berlowitz et al., 1998; Paramore et 
al., 2001). 
Hypertension is an important public-health challenge in the world due to its high 
frequency and associated risks of cardiovascular and kidney diseases (Whelton, 1994; 
He and Whelton, 1997). It has been identified as the primary risk factor for death, and is 
the third cause of disability-adjusted life-years (Ezzati et al., 2002). Its prevalence in 
different areas of the world has been extensively reported (Gupta, 1999; Halberstein, 




Kearney et al. (2005) collected data from different areas of the world to estimate the 
prevalence and burden of hypertension in 2000, and to estimate the global burden in 
2025. Using MEDLINE, supplemented by searching the bibliographies of retrieved 
articles manually, they have searched the published literature from Jan 1, 1980, to Dec 
31, 2002. They included sex age-specific prevalence of hypertension studies in 
representative population samples. According to Kearney et al. (2005), 26.4 % of the 
world’s male adult population in 2000 and 26.1 % of women suffered from 
hypertension. By 2025, 29.2 % of the adult population was predicted to have 
hypertension, and of these, 29 % was predicted in men and 29.5 % in women. However, 
the study did not mention the reasons behind this difference. World regions with the 
highest prevalence of hypertension had a rate, which is about twice the rate of areas 
with the lowest prevalence of hypertension. In men, the highest prevalence was in Latin 
America and the Caribbean areas, whereas for women the highest prevalence was in the 
former socialist economies. The lowest prevalence of hypertension for both men and 





Figure 1.1  Estimated Prevalence of Hypertension in People Aged 20 Years and 
Older for 2000 and 2025 (Kearney et al., 2005). 
Whereas:  
Established market economies: USA, Canada, Spain, England, Germany, Greece, 
Italy, Sweden, Australia and Japan 
Former socialist economies: Slovakia 
Latin America and the Caribbean: Mexico, Paraguay and Venezuela 
Middle Eastern crescent: Egypt and Turkey 
Other Asia and islands: Korea, Thailand and Taiwan 
Sub-Saharan Africa: South Africa, Cameroon, Tanzania and Zimbabwe 
 
Because of the expected changes in the age of the population between 2000 and 2025, 
the worldwide prevalence of hypertension was predicted to increase by 9 % in men and 
13 % in women (Kearney et al., 2005). The relation between gender and the prevalence 
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of hypertension according to world geographical area is as in the following: four areas 
had higher prevalence in men and four had higher prevalence in women. At young ages, 
prevalence of hypertension is higher in men than in women, while in older people they 
are higher in women than in men. Figure 1.2 shows approximation of the absolute 
number of hypertensive individuals in different world areas (Kearney et al., 2005). 
 
 
Figure 1.2  Number of Hypertensive Individuals in Different World Areas (Kearney 
et al., 2005). 
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The estimated total number of people with hypertension in 2000 was around 972 
million; about 333 million were in economically developed countries, and around 639 
million in economically developing countries (Kearney et al., 2005). The greatest 
number of hypertensive individuals was found to be in the established market 
economies. Nevertheless, both economically developed and developing areas had many 
individuals with hypertension, and about two-thirds of these hypertensive individuals 
were in developing areas. In 2025, the number of adult individuals with hypertension is 
expected to increase by 60 % to 1.56 billion. Although the number of individuals with 
hypertension in economically developed countries was expected to increase by 24 % 
from 333 million to 413 million, a rise of 80 % was expected for economically 
developing countries from 639 million to 1.15 billion. Almost three-quarters of the 
world’s hypertensive population will be in the economically developing countries by 
2025 (Kearney et al., 2005). 
 
1.1.4 Hypertension Prevalence in Malaysia 
About 30 % (around 2.6 million) of Malaysian adults at the age of 30 years or older 
have hypertension (Lim et al., 2004). Women have a higher prevalence of hypertension 
than men do. Malay women and women of other indigenous groups have the highest 
age-adjusted prevalence of hypertension, whereas Chinese and Indian women have the 
lowest prevalence. Malay women have a higher prevalence of hypertension than all 
other sex-ethnic groups (Lim et al., 2004). 
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According to Lim, et al. (2004), Malay women and women from other indigenous 
groups have the highest mean systolic blood pressure, Chinese and Indian men had the 
highest diastolic blood pressure, whereas Chinese and Indian women have the lowest 
diastolic blood pressure as well as systolic blood pressure. The mean systolic blood 
pressure rises with growing age, and diastolic blood pressure is likely to decline beyond 
the age of 50-55 years in all groups. Young women have lower systolic blood pressure 
than men do. Young Malay women and those from other indigenous groups (aged 35-
40) have higher mean systolic blood pressure than the young women do in the Chinese 
and Indian groups for the whole age range.  
In all groups, normotensive men have higher mean systolic blood pressure and diastolic 
blood pressure than women. Nevertheless, among individuals with hypertension who 
are treated and untreated, the women have higher mean systolic blood pressure than 
men, except in the Indian population. Mean diastolic blood pressure in individuals with 
hypertension who are treated and untreated is higher for men than for women. There is 
no difference in mean systolic blood pressure and diastolic blood pressure between 
treated and untreated individuals with hypertension in all groups. A difference in mean 
blood pressure between treated and untreated hypertensives is found in other indigenous 
ethnic group (Lim et al., 2004).  
According to Lim and colleagues (2004), about one third of people with hypertension 
are aware of their hypertension status, 31 % had never been treated and only 23% are on 
antihypertensive drugs. Barely, 6 % of people with hypertension have controlled blood 
pressure (less than 140/90). In all ethnic-age groups, women are more aware of their 
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hypertension status than men are. Women are also more likely to be treated and to 
remain on treatment with antihypertensive drugs. Among people with hypertension 
being treated, only 26 % achieved blood pressure control. Men tend to have better blood 
pressure control than women do. Blood pressure control deteriorates with increasing age 
except for Indians and other indigenous men. However, another most recent study on 
the prevalence of hypertension in Malaysia reported that the mean systolic blood 
pressure in men was significantly higher than that in women. Likewise, the mean 
diastolic blood pressure in men was significantly higher than that in women (Rampal et 
al., 2008).  
In the most recent Malaysian study by Rampal, et al. (2008) (Table 1.4), the prevalence 
of hypertension in subjects aged ≥ 15 years was 27.8 % and it increased with age in 
both genders. Hypertension was more prevalent in males than females in subjects aged 
between 15 to 39 years. Generally, mean systolic blood pressure was 122 mmHg and 
mean diastolic blood pressure was 79 mmHg. Both means (systolic 124 mmHg and 
diastolic 80 mmHg) for males were significantly higher than those for females (systolic 
121 mmHg and diastolic 78 mmHg).  
The prevalence of hypertension increased with age in all ethnic groups. For subjects 
aged ≥ 15 years, the Chinese had the highest prevalence (30.6 %), followed by the 
Malays (26.7 %) and the Indians (25.1 %) (Table 1.5). The indigenous people from the 
state of Sarawak, ‘the Sarawak Bumiputra’, had a higher prevalence of hypertension 
(31.1 %) than other ethnic groups (Rampal et al., 2008). Rasool et al., (2000) reported 
that the Malays might have higher beta-adrenergic receptor sensitivity than the Chinese 
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and Indians, an observation that could explain the observed difference in hypertension 
prevalence between the ethnic groups in both studies.  
Only 34.6 % were aware of their hypertension. Females were more aware of their 
hypertensive status (40.6 %) than males (29.4 %) (Table 1.6). Only 32.4 % of the 
hypertensive subjects in the study were taking antihypertensive drugs and of these, only 
26.6 % had a controlled blood pressure (≤ 140/90 mmHg). Overall, 8.6 % of 
hypertensive subjects had their blood pressure controlled (Rampal et al., 2008).  
Previous research conducted by the Malaysian Ministry of Health in 2006 reported that 
the prevalence of hypertension was 42.6 % amongst subjects aged ≥ 30 years. 
Additionally, about 36% of hypertensive subjects were aware that they had 
hypertension and about 87.7% of them were receiving treatment. However, only 26% of 
those subjects who are on treatment were able to achieve the target blood pressure 
(Ministry of Health, 2006). The prevalence of hypertension remained high but may be 
slightly decreased since 2006. In 2009, it is estimated that there are about 4.8 million 




1.1.5 Management of Hypertension 
The main goal of antihypertensive treatment (i.e. pharmacological and non-
pharmacological therapy) is to not only reduce blood pressure, but also to prevent 
cardiovascular and other complications related to elevated blood pressure, to prolong 
existence, and to improve the quality of life. In the meanwhile, drug approval agencies 
have approved many new drugs for antihypertensive treatment on the basis that 
treatment will decrease blood pressure as an intermediate endpoint. As far as controlling 
blood pressure is concerned, policies call for decreasing both systolic and diastolic 
blood pressure because of the evidence of the risk of isolated systolic hypertension in 
old people (Staessen et al., 2000).  
Hypertension is associated with cardiovascular and renal diseases. Collins and 
MacMahon (1994) and Staessen et al. (2001; and 2002b) provided a thorough 
account of the outcome trials in hypertension and the effects of treatments on primary 
and secondary endpoints. Additionally, most of the evidences on the effects of blood 
pressure on the risks of cardiovascular disease derived from prospective observational 
studies of the associations between blood pressure and the incidence of stroke and 
coronary heart disease, and from randomized trials of antihypertensive drug therapy 
(Collins and MacMahon, 1994; Chobanian et al., 2003a; Lawes et al., 2008). The 
evidence from observational studies is more applicable to the eventual effects of 
prolonged blood pressure differences on stroke and coronary heart disease risk. The 
worldwide burden of diseases attributable to hypertension is about 7.6 million 
premature deaths and 92 million disability-adjusted life years. Additionally, half of 
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strokes and ischemic heart disease worldwide were attributable to hypertension (Lawes 
et al., 2008). On the other hand, the evidence from randomized trials is more relevant to 
assessing how rapidly, and to what degree, the epidemiologically expected reductions in 
stroke or in coronary heart disease are produced by lowering blood pressure in middle 
and old age (Collins and MacMahon, 1994). 
Ambulatory measurement of blood pressure plays an important role in the 
management of hypertension. Staessen et al. (2001) investigated whether ambulatory 
measurement of pulse pressure and mean pressure can refine risk stratification. Their 
study enrolled 808 older patients with high isolated systolic hypertension. Patients aged 
≥ 60 years were randomized to nitrendipine 10-40 mg/day with the possible addition of 
enalapril 5-20 mg/day or hydrochlorothiazide 12.5-25 mg/day or to matching placebos. 
Pulse pressure and mean pressure were determined from six conventional blood 
pressure readings and from 24 hours ambulatory recordings. Later, they computed the 
relative hazard rates associated with 10-mmHg increase in pulse pressure or mean 
pressure. As a result, they found that in older patients with isolated systolic 
hypertension higher pulse pressure estimated by 24 hour ambulatory monitoring was a 
better predictor of undesirable outcomes than conventional pulse pressure, whereas 
conventional and ambulatory mean pressures were not correlated with a worse outcome 
(Staessen et al., 2001). 
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1.1.5.1 Lifestyle Intervention  
Sodium restriction is an effective nutritional therapy in patients with hypertension 
(Whelton et al., 1997; Hermansen, 2000; Chobanian et al., 2003a). In the Dietary 
Approaches to Stop Hypertension (DASH) trial, study subjects were given meals with 
different salt levels for more than 4 weeks. The study diet was rich in fresh fruits, 
vegetables, and low-fat dairy products. As a result, for both the DASH and traditional 
diets, the lower the salt intake, the lower was the blood pressure (Sacks et al., 2001). 
Likewise, calcium food supplementation may also help to reduce blood pressure 
(Griffith et al., 1999; Zemel, 2001).  
In addition, physical activity can lower blood pressure. Regular aerobic exercise for 
at least half an hour a day for at least 4 days per week is ideal for most 
hypertensive patients (Fagard, 2001). Patients with target-organ disease should 
consult their physicians before starting an exercise programme to see whether 
they are fit to do that specific program or not. Additionally, cigarette smoking is 
a major independent risk factor for cardiovascular disease and stopping smoking can 
help in diminishing blood pressure (Mikkelsen et al., 1997). Because of this fact, 
hypertensive patients, who smoke, should be counseled and encouraged to stop 







Figure 1.3 Hypertension Treatment Algorithm (Chobanian et al., 2003b). 
 
1.1.5.2 Pharmacological Treatment  
The most important indication for antihypertensive drugs is hypertension (Appendix D), 
and new drugs are being introduced and promoted in the health care market (Woodwell 
and Cherry, 2004). Although the choices of the antihypertensive drug affect the 
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effectiveness of the therapy, these choices are sometimes taken based on promotional 
activities, which might be biased (Blumenthal, 2004).  
The use of antihypertensive drugs with appropriate lifestyle modifications and self 
blood pressure monitoring can control the blood pressure in most of hypertensive 
patients (Singer et al., 2004; Canzanello et al., 2005). However, poor control of blood 
pressure has been shown in different samples of population from different countries in 
the world (Wolf-Maier et al., 2004). Wolf-Maier et al. (2004) estimated the relative 
impact of hypertension treatment strategies in Germany, Sweden, England, Spain, Italy, 
Canada, and the United States. Their study found that 66 % of 35 to 64 years aged 
hypertensive persons in the United States had controlled blood pressure at 160/95 
mmHg, compared with 49 % in Canada and 23 % to 38 % in Europe. Around 29% of 
hypertensives in the United States, 17 % in Canada, and ≤ 10% in European countries 
had their blood pressure controlled at the 140/90 mmHg threshold. Two thirds to three 
quarters of the hypertensives in Canada and Europe were untreated compared with 
slightly less than half in the United States at the 140/90 mmHg cut-point. In addition to 
the higher prevalence of hypertension, low treatment and control rates in Europe might 
contribute to a higher burden of cardiovascular disease risk attributable to hypertension. 
Hypertension treatment and control status vary between Europe and North America. 
Clinical practice guidelines to manage hypertension have been developed to help health 
care practitioners to decide on proper health care options for hypertensive patients 
rationally. When implemented successfully, they must improve quality of care (Audet et 
al., 1990; Chassin, 1990). Although the guidelines are widely spread among health care 
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practitioners, their effect on changing physician behavior in managing the disease is 
limited (Woolf, 1993; Hayward, 1997). 
The Seventh Report of the Joint National Committee on Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) was designed to help clinicians to manage 
hypertension (Chobanian et al., 2003a). The guidelines recommended diuretics as first-
line therapy for uncomplicated hypertension. This recommendation was based on 
published controlled clinical trials data that showed reduced morbidity and mortality 
with the use of diuretics. Additionally, the guidelines state that thiazide-type diuretics 
must be used in most patients with uncomplicated hypertension, either alone or 
combined with drugs from other classes. However, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers are 
used in hypertensive patients who are with certain high-risk conditions (Chobanian et 
al., 2003a). Likewise, the latest Malaysian clinical practice guidelines recommended 
diuretics, ACE inhibitors, ARBs and CCBs as the choice of first-line treatment in the 
form of monotherapy for patients with uncomplicated hypertension with no compelling 
indications (Malaysian Clinical Practice Guidelines on the Management of 
Hypertension, 2008). The recommendation was based on studies that have compared 
thiazides with beta-blockers and found that rates of withdrawal because of adverse 
effects were lower with thiazides than beta-blockers and that thiazides were associated 
with lower incidence of cardiovascular events. Moreover, studies demonstrated that 
thiazides lowered systolic blood pressure more than beta-blockers and calcium channel 
blockers (Medical Research Council, 1992; Veterans Administration Cooperative Study 
